BCL2L1 and acute myeloid leukemia: Since 20(S)-PPD is a dual inhibitor of both Bcl-XL and MCL-1 and exhibits minimal toxicity, it suggests that the combination of 20(S)-PPD and venetoclax may be a potential strategy for treating AML.